-
Launching of ERA-CVD LYMIT-DIS
In this new project, five european research teams join together with the aim to develop new treatment options for patients suffering from Heart Failure with Preserved Ejection Fraction.
Project start date 06/03/2017
(Kick-off meeting to be held in Rouen, France in September 2017 )
Heart Failure (HF) represents a serious health challenge, with an estimated 6.5 million patients suffering from HF in the European Union, which corresponds to the combined current population of Brussels, Madrid, and Paris. Our collaborative research project, LYMIT-DIS, is aimed at improving diagnosis, prognosis, and development of new treatments for HF, focusing on HF with preserved Ejection Fraction (HFpEF). This type of HF with diastolic cardiac dysfunction, affects more than 50% of HF patients, notably women, and is linked to metabolic syndrome, an increasingly common condition characterized by insulin resistance, abdominal obesity, dyslipidemia, and hypertension.
Inserm U1096
Research performed in Inserm U1096 Unit in Rouen, concerns evaluation of the mechanisms behind and novel treatments of cardiovascular diseases, focusing on vascular protection and improvement of cardiac contractile function. This research is transversal, and performed both in experimental models and in human.
Vascular research:
Our work mostly concerns the protection of vascular endothelial cells in the context of cardiovascular risk factors or cardiovascular diseases (hypertension, diabetes, myocardial infarction, heart failure etc. ). We also investigate new biotherapy approaches for stimulation of cardiac angiogenesis and lymphangiogenesis.
Cardiac research:
Development and assessment of new treatments of heart failure, as well as the clinical evaluation of percutaneous aortic valve replacement.